RJA
EW icon

Ross\Johnson & Associates’s Edwards Lifesciences EW Stock Holding History

Ross\Johnson & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160 Sell
2
-9
-82% -$742 ﹤0.01% 188
2025
Q4 		$938 Buy
11
+9
+450% +$739 0.02% 100
2025
Q3 		$156 Hold
2
– – ﹤0.01% 185
2025
Q2 		$156 Hold
2
– – ﹤0.01% 185
2025
Q1 		$144 Buy
+2
New +$143 ﹤0.01% 334

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ross\Johnson & Associates's EW Position: Q1 2026 in Review

Ross\Johnson & Associates reduced its Edwards Lifesciences (EW) stake by 82% in Q1 2026, selling an estimated $742 and leaving 2 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #188.

Ross\Johnson & Associates first reported a position in EW in Q1 2025 and has held it in 5 quarters since. The position peaked at $938 in Q4 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Ross\Johnson & Associates held 2 shares of Edwards Lifesciences worth $160 as of Q1 2026.
  • Ross\Johnson & Associates sold 9 Edwards Lifesciences shares in Q1 2026, an estimated $742.
  • Edwards Lifesciences made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q1 2026, its #188 holding.
  • Ross\Johnson & Associates first reported a position in Edwards Lifesciences in Q1 2025 and has held it in 5 quarters since.
  • Ross\Johnson & Associates's Edwards Lifesciences position peaked at $938 in Q4 2025.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.